The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castrationresistant prostate cancer: Post hoc analysis of Korean patients
Purpose: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial. Materials and Methods: Asymptomatic or mildly symptomatic chemotherapy-naïve men with metastatic castration-r...
Main Authors: | Choung-Soo Kim, Ad Theeuwes, Dong Deuk Kwon, Young Deuk Choi, Byung Ha Chung, Hyun Moo Lee, Kang Hyun Lee, Sang Eun Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Urological Association
2016-05-01
|
Series: | Investigative and Clinical Urology |
Subjects: | |
Online Access: | https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-57-174.pdf |
Similar Items
-
Abiraterone and MDV3100 inhibits the proliferation and promotes the apoptosis of prostate cancer cells through mitophagy
by: Jingli Han, et al.
Published: (2019-12-01) -
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
by: Anna R. Michmerhuizen, et al.
Published: (2020-02-01) -
Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
by: Minggen Yang, et al.
Published: (2021-09-01) -
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial
by: Nancy Devlin, et al.
Published: (2017-06-01) -
Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)